Azathioprine therapy for acquired myasthenia gravis in five dogs

Journal of the American Animal Hospital Association

Volumn 35, Issue 5, 1999, Pages 396-402

  Dewey, C W ^a   Coates, J R ^a   Ducote J M ^a   Meeks, J C ^b   Fradkin, J M ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Gulf Coast Veterinary Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; PREDNISONE; PYRIDOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOG; FEMALE; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; MEGAESOPHAGUS; MYASTHENIA GRAVIS; NONHUMAN; OSTEOSARCOMA; PARAPLEGIA; REMISSION; SURVIVAL TIME;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032878781     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/15473317-35-5-396     Document Type: Article

References (33)

1. Dewey CW. Acquired myasthenia gravis in dogs - part I. Comp Cont Ed Pract Vet 1997;19(12):1340-54.
2. Dewey CW, Bailey CS, Shelton GD, Kass PH, Cardinet GH. Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995), J Vet Int Med 1997;11(2):50-7.
3. Shelton GD, Willard MI, Cardinet GH, Lindstrom J. Acquired myasthenia gravis: selective involvement of esophageal and faciat muscles. J Vet Int Med 1990:4(6):281-4.
4. King LG, Vite CH. Acute fulminating myasthenia gravis in five dogs. J Am Vet Med Assoc 1998;212(6):830-4.
5. Dewey CW. Acquired myasthenia gravis in dogs - part II. Comp Cont Ed Pract Vet 1998;20(1):47-59.
6. Beekman R, Kuks JBM. Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neural 1997;244:112-8.
7. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330(25):1797-810.
8. Watson RF, Lisak RP. Myasthenia gravis: an overview. In: Lisak RP, ed. Handbook of myasthenia gravis and myasthenic syndromes. New York: Marcel Dekker, 1994:1-19.
9. Levin KH, Richman DP. Myasthenia gravis, In: Adachi M, Scher JH. eds. Current trends in neurosciences: neuromuscular disease. New York: Igaki-Shoin, 1990:296-317.
10. Hohlfeld R, Toyka KV. Therapies. In: DeBaets MH, Oosterhuis HJG. eds. Myasthenia gravis. London: CRC Press, 1993:236-61.
11. Maddison JE, Waelchli-Suter CM, Johnson RP. Clinical remission after corticosteroid therapy of acquired myasthenia in three dogs. J Am Vet Med Assoc 1984:184(7):845-8.
12. Van Heerden J, Van Schouwenburg SJ. The use of corticosteroids in a dog with myasthenia gravis, J S Afr Vet Assoc 1983;54(2): 135-7.
13. LeCouteur RA, Luttgen PJ. Disorders of peripheral nerves. In: Morgan RV. ed. Handbook of small animal practice. 2nd ed. Now York: Churchill Livingstone. 1992:303-22.
14. Miller E. Immunosuppressive therapy in the treatment of immune-mediated disease. J Vet Int Med 1992;6(4):206-13.
15. Machkhas H, Harali Y, Rolak LA. Clinical pharmacology of immunosuppressants: guidelines for neuroimmunotherapy. In: Rolak RA, Harati Y. eds. Ncuroimmunology for the clinician. Boston: Butterworth-Heinemann. 1997:77-104.
16. Johns TR. Long-term corticosteroid treatment of myasthenia gravis. Ann NY Acad Sci 1987;505:568-83.
17. Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986;36:729-32.
18. Gooch CL. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rolak RA, Harati Y, eds. Neuroimmunology for the clinician. Boston: Butterworth-Heinemann. 1997:263-99.
19. Cosi V, Lombardi M, Erbetta A, Piccolo G. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis. Acta Neural 1993;15:123-31.
20. Matell G, Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 1987;505:588-94.
21. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997;62:156-62.
22. Shelton GD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions of the acetylcholine receptor. Neurol 1988;38:1417-23.
23. Henze T. Myasthenia gravis and myasthenic syndromes. Part I. Myasthenia gravis. Drugs of Today 1997;33(7):485-98.
24. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1986;43:155-6.
25. Gajdos P, Elkharrat D, Chevret S, et al. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis, Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993;56:1157-63.
26. Anstey A, Lear JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. Bio Drugs 1998;9(1):33-47.
27. Shah A, Lisak RP. Immunopharmacologic therapy in myasthenia gravis. Clin Neuropharmacol 1993;16(2):97-103.
28. Kawabata TT. Immunopharmacology. In: Brody TM, Larner J, Minneman KP, eds. Human pharmacology: molecular to clinical. 3rd ed. St. Louis: Mosby-Year Book. 1998:621-37.
29. Allen DG, Pringle JK, Smith DA, Conlon PD, Burgmann PM. Handbook of veterinary drugs. Philadelphia JB Lippincotl. 1993:72-3.
30. Ogilvie GK, Felsburg PJ, Harris CW. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response, Vet Immunol Immunopathol 1988:18:119-27.
31. Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988;192(9):1316-8.
32. Bartges JW, Hansen D, Hardy RM. Outcome of 30 cases of acquired myasthenia gravis in dogs (1982-1992). J Vet Int Med (abs) 1997;11(2): 144.
33. Palace J, Newsom-Davis J. Lecky B, et al, A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurol 1998;50:1778-83.